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Abstract The in vitro modulation of the proliferation of human 
peripheral blood lymphocytes by different synthetic peptides 
derived from milk proteins was investigated. Therefore, prolif- 
eration changes were followed up after incorporation of BrdU 
into the DNA, and the influence on protein biosynthesis was 
measured using the [3H]leucine incorporation test. Tyr-Gly and 
Tyr-Gly-Gly significantly enhanced (maximal 90 and 35%, 
respectively) the proliferation of PBL. For 13-casomorphin-7 and 
13-casokinin-10, lymphocyte proliferation was suppressed at 
lower concentrations, but stimulated at higher concentrations 
(->10 -7 mol/l). Protein synthesis was stimulated (maxima at 
25%) only with Tyr-Gly and Tyr-Gly-Gly. The findings point to 
a need for further studies on the possible function of peptides 
derived from milk proteins as orally bioavailable immunopoten- 
tiatory compounds. 
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I. Introduction 
A wide range of biologically active peptides which can be 
liberated from milk proteins during enzymatic in vitro or in 
vivo digestion have been identified (for review see [1]). Casein 
phosphopeptides and casomorphins have already found inter- 
esting applications, both as pharmaceutical preparations and 
as dietary supplements. Casein derived immunopeptides in- 
cluding immunopeptides from aSl-casein (residues 194-199) 
and [3-casein (residues 63-68 and 191-193) have been shown 
to stimulate phagocytosis of sheep red blood cells by murine 
peritoneal macrophages, and to exert a protective effect 
against Klebsiella pneumoniae infection in mice after intrave- 
nous treatment [2,3]. There are various hypotheses about the 
physiological action of such peptides. They might stimulate 
the proliferation and maturation of T-cells and natural killer 
cells for the defence of the newborn against different bacteria, 
particularly enteric bacteria. 
This paper reports on the immunoreactivity of human per- 
ipheral blood lymphocytes timulated or suppressed by var- 
ious synthetic peptides corresponding to bioactive sequences 
of bovine milk proteins. 
*Corresponding author. Fax: (49) (431) 609222. 
**Dedicated to Prof. Detlev Kayser on the occasion of his 65th 
birthday. 
Abbreviations. PBL, peripheral blood lymphocytes; BrdU, 5-bromo- 
2'-deoxyuridine; ConA, concanavalin A; TMB, tetramethylbenzidine; 
PBS, phosphate-buffered saline. 
2. Materials and methods 
2.1. Materials 
RPMI-1640, Ficoll-Hypaque, macromolecular dextran, Con A, pe- 
nicillin/streptomycin solution, Tyr-Gly (YG), Tyr-Gly-Gly (YGG), [3- 
casomorphin-7 (YPFPGPI), all cell culture dishes and multiwell plates 
were from Sigma (Deisenhofen, Germany). BrdU-proliferation assay 
kit was obtained from Boehringer (Mannheim, Germany). L-[4,5- 
3H]Leucine (128 Ci/mmol) was purchased from Amersham Life 
Science (Braunschweig, Germany). All other substrates and chemicals 
were obtained from the specific suppliers as indicated. 
2.2. Peptide synthesis 
13-Casokinin-10 (YQQPVLGPVR) was synthesized by the Fmoc- 
polyamide solid-phase method [4] using a resin derivatised with 
Fmoc-Arg(Mtr) (Novabiochem, Cambridge) and a continuous flow 
peptide synthesizer as described in reference; the overall yield of the 
HPLC-purified peptide was 53.2%. 
2.3. Isolation of human peripheral blood lymphocytes ( PBL ) 
PBL in the heparin-anticoagulated blood of normal subjects were 
enriched according to the method of Boyum [5]. Briefly, buffy coat 
was diluted 2-fold with PBS (pH 7.2) and PBL together with mono- 
cytes were recovered by centrifugation on Ficoll-Hypaque cushions. 
Cells were washed twice with 0.9% NaCI and subsequently diluted in 
RPMI-1640 medium containing 10% heat-inactivated calf serum (Sig- 
ma, Deisenhofen, Germany) and 2 lag/ml Con A in an atmosphere 
containing 5% CO2. After 24 h of differentiation, PBL were separated 
from adherent monocytes and diluted in fresh medium for further 
assays. 
2.4. Assessment of PBL proliferation 
To quantify PBL proliferation the colorimetric Cell Proliferation 
ELISA (Boehringer Mannheim, Germany) was used according to 
manufacturer's instructions. Cells (2× 105/200 ~tl) cultured in a 96- 
well microtiter plate in the present of various peptides were pulsed 
with 5-bromo-2'-deoxyuridine (BrdU) for 12 h. Incorporation of 
BrdU into the DNA was detected by the anti-BrdU antibody perox- 
idase conjugate (POD). The amount of POD retained in the immu- 
nocomplex was quantified by a substrate reaction using TMB. Results 
were read out on an ELISA spectrophotometer at 450 nm (reference 
wavelength: 620 nm). 
2.5. Assessment of protein biosynthesis 
In order to demonstrate he influence of bioactive peptides on the 
protein biosynthesis of PBL the [3H]leucine incorporation assay was 
used [6]. Therefore, 2× l0 p PBL in 200 Ixl of leucine-free RPMI-1640 
were added to each of 96 wells of microtiter plates with an increasing 
amount of the respective peptide or Con A as positive control. After 
18 h, 1 p.Ci of [3H]leucine was added to each well and incubation was 
continued for 6 h at 37°C. The incubations were stopped by removing 
the cells onto Whatman 3MM glass fiber plates. The incorporation of 
[aH]leucine into acid-precipitable material was measured by liquid 
scintillation counting. 
3. Results and discussion 
The effects of Tyr-Gly, Tyr-Gly-Gly, 13-casomorphin-7 as 
well as I~-casokinin-10 on the proliferation of human periph- 
eral blood lymphocytes activated with ConA were examined 
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F g. 1. Effect of Tyr-Gly (e) and Tyr-Gly-Gly (11) on incorporation 
ot BrdU by human lymphocytes activated with ConA. Each data 
p,4nt represents he mean percentage change; the results have been 
reproduced five times with an S.E.M.-< 20%. Cells cultured in med- 
item only gave an absorbance of (A45o--A62o) = 0.484 + 0.026. 
il vitro by separately quantifying the incorporation of BrdU 
a'ter 72 h and [3H]leucine after 18 h to assess alterations in 
I~,NA synthesis and protein synthesis, respectively. Tyr-Gly 
a id  Tyr-Gly-Gly significantly enhanced the incorporation of 
BrdU by PBL at respective concentrations of 10 -11 to 10 -4 
nol/1 (Fig. 1). Maximal stimulation was achieved with 10 -4 
n,ol/1 Tyr-Gly and 10 -s mol/1 Tyr-Gly-Gly, respectively. It
should be stressed that Tyr-Gly already revealed 93% of max- 
i lml stimulation at 10 -9 mol/1, and Tyr-Gly-Gly showed 74% 
o," maximal stimulation at 10 -12 mol/l. In contrast, 13-caso- 
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Fig. 2. Effect of I~-casokinin-10 (v) and [3-casomorphin-7 (0) on 
incorporation of BrdU by human lymphocytes activated with 
('onA. Each data point represents he mean percentage change; the 
results have been reproduced five times with an S.E.M.-< 17% and 
10%, respectively. 
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morphin-7 and ~-casokinin-10 suppressed the incorporation 
of BrdU at lower concentrations, but revealed stimulation at 
higher concentrations (Fig. 2). Protein synthesis was enhanced 
with Tyr-Gly and Tyr-Gly-Gly (Fig. 3); however, no marked 
effect was found with ~-casomorphin-7 and 13-casokinin-10 
(data not shown). 
The peptides Tyr-Gly and Tyr-Gly-Gly are partial se- 
quences in the primary structure of bovine ~c-casein and c~- 
lactalbumin, respectively. Recently, these peptides were used 
for immunotherapy of human immunodeficiency virus infec- 
tion: In a large multicenter t ial, a dialysed leukocyte xtract 
from normal donors in which Tyr-Gly-Gly and Tyr-Gly are 
thought o be the nonspecific active components was applied 
to inhibit the development of infections in patients with pre- 
AIDS. Encouraging results after a bi-weekly treatment of 93 
patients with an AIDS-related complex showed a significant 
reduction either to progress to a clinically relevant endpoint 
or to AIDS [7]. 
[~-Casomorphin-7 derived from [~-casein [8] was used as a 
possible immunostimulating substrate since it is a ligand of I.t- 
type opioid receptors that have also been found on the surface 
of human T-lymphocytes [9,10]. Furthermore, casomorphins 
may function as both opioid agonists and inhibitors of angio- 
tensin-converting-enzyme (ACE) [11]. 13-Casokinin-10 is a 
non-opioid peptide fragment of casein that inhibits ACE [4]. 
A common structural feature of several ACE-inhibitory pep- 
tides and some immunomodulatory peptides is the presence of 
arginine as the C-terminal residue [12-15]. It is assumed that 
the positively charged arginine residue contributes ubstan- 
tially to the bioactivity of these peptides. 
Milk proteins are precursors of different bioactive peptides 
that are inactive within the sequence of the precursor protein 
and can be released uring gastrointestinal passage [1]. This 
also applies to the immunomodulating peptides investigated in 
the present study. Such peptides may interact with the gut- 
associated lymphoid tissue (GALT). Moreover, di-and tripep- 
tides like Tyr-Gly and Tyr-Gly-Gly can, in principle, pass 
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Fig. 3. Effect of Tyr-Gly (e) and Tyr-Gly-Gly (11) on uptake of 
[aH]leucine by human lymphocytes activated with ConA. Each data 
point represents he mean percentage change; the results have been 
reproduced five times with an S.E.M.-< 9%. Cells cultured in med- 
ium only gave 22070 + 960 cpm. 
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across the intestine in quantitatively significant amounts to 
reach peripheral lymphocytes. Taken together, the effects of 
these peptides on PBL lend support to the claim that several 
as yet unknown immunomodulatory sequences are located 
within bovine milk proteins. These peptides may function as 
orally bioavailable compounds. Thus, the results justify 
further experiments, e.g. using cells from Peyer's patches, to 
elucidate the putative physiological significance as well as the 
structure-activity relationship of immunopotentiatory peptides 
derived from milk proteins. 
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